Recent Developments in Tyrosine Kinase Inhibitor-based Nanotherapeutics for EGFR-resistant Non-small Cell Lung Cancer

Area of Science:

• Oncology
• Nanomedicine
• Pharmacology

Background:

• Acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy poses a significant challenge in treating non-small cell lung cancer (NSCLC).
• The emergence of advanced EGFR mutations drives this resistance, necessitating the development of novel therapeutic strategies.
• Current treatment limitations underscore the need for innovative approaches to overcome drug resistance in NSCLC.

Purpose of the Study:

• To review and summarize nano-formulations developed to combat EGFR-TKI resistance in NSCLC.
• To highlight the efficacy of these nanomedicine approaches in preclinical settings.
• To provide insights into the design principles of nanoparticles for treating resistant NSCLC.

Main Methods:

• Literature review of preclinical studies on nanomedicine for EGFR-TKI-resistant NSCLC.
• Analysis of studies reporting *in vitro* and *in vivo* efficacy of nano-formulations.
• Synthesis of findings related to nanoparticle design and nanosystem development.

Main Results:

• Nanomedicine approaches demonstrate potential for targeted delivery and sustained release of therapeutic agents in EGFR-TKI-resistant NSCLC models.
• Preclinical studies show promising efficacy of various nano-formulations in both *in vitro* and *in vivo* settings.
• Insights into the design of effective nanoparticles and multifunctional nanosystems for overcoming drug resistance were identified.

Conclusions:

• Nanomedicine presents a viable strategy to address EGFR-TKI resistance in NSCLC.
• Nano-formulations offer a promising therapeutic avenue for patients with resistant NSCLC.
• Further development of nanomedicine holds potential for improved treatment outcomes in EGFR-TKI-resistant NSCLC.